版本:
中国

BRIEF-FDA grants priority review for Amgen's Blincyto supplemental biologics license application

March 29 Amgen Inc

* FDA grants priority review for Amgen's Blincyto® (blinatumomab) supplemental biologics license application

* Amgen Inc - Prescription Drug User Fee Act (PDUFA) target action date is Aug. 14, 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐